2,7-diazabicyclo[3.3.0]octanes as novel h5-HT receptor agonists

Bioorg Med Chem Lett. 1999 Sep 6;9(17):2491-6. doi: 10.1016/s0960-894x(99)00409-6.

Abstract

The conformational restriction of a (benzylamino)methyl substituted pyrrolidine to form 2,7-diazabicyclo[3.3.0]octanes has led to a series of compounds with high affinity at the h5-HT1D receptor as well as dramatically increased concentrations in the hepatic portal vein following oral administration.

MeSH terms

  • Administration, Oral
  • Animals
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
  • Bridged Bicyclo Compounds, Heterocyclic / chemistry
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • CHO Cells
  • Cricetinae
  • Receptor, Serotonin, 5-HT1D
  • Receptors, Serotonin / drug effects*
  • Recombinant Proteins / drug effects
  • Serotonin Receptor Agonists / administration & dosage
  • Serotonin Receptor Agonists / chemistry
  • Serotonin Receptor Agonists / pharmacology*

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Receptor, Serotonin, 5-HT1D
  • Receptors, Serotonin
  • Recombinant Proteins
  • Serotonin Receptor Agonists